加载中
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
前收盘价
US$7.56
+US$0.02 · +0.27%
盘前
US$7.58
+US$0.02 · +0.26%
10月13日 4:00 ET
盘中时间采用ET。市场数据可能有所延迟。
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
日内区间
当前US$7.56
52周区间
当前US$7.56
盘中时间采用ET。市场数据可能有所延迟。
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
日内区间
当前US$7.56
52周区间
当前US$7.56
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5182.3万 USD | 6372.3万 USD | 5844.3万 USD | 5149.4万 USD | 4352.2万 USD |
| 销货成本 | 657.4万 USD | 562.6万 USD | 528.1万 USD | 454万 USD | 440.6万 USD |
| 毛利 | 4524.9万 USD | 5809.7万 USD | 5316.2万 USD | 4695.4万 USD | 3911.6万 USD |
| 研究与开发 | 1.97亿 USD | 1.28亿 USD | 6105.5万 USD | 5346.2万 USD | 5008.3万 USD |
| 销售、一般及管理费用 | 1.18亿 USD | 1.02亿 USD | 7448.9万 USD | 7214.6万 USD | 6707万 USD |
| 营业费用 | 3.15亿 USD | 2.3亿 USD | 1.36亿 USD | 1.26亿 USD | 1.17亿 USD |
| 利息收入 | 1835.5万 USD | 2028.2万 USD | 398.3万 USD | 79.8万 USD | 3.3万 USD |
| 利息支出 | 1183.5万 USD | 1357.7万 USD | 1133.8万 USD | 702.2万 USD | 667.1万 USD |
| 折旧和摊销 | 432.3万 USD | 378.6万 USD | 298.3万 USD | 210.9万 USD | 242.1万 USD |
| 营业利润 | −2.7亿 USD | −1.72亿 USD | −8238.2万 USD | −7865.4万 USD | −7803.7万 USD |
| 净利润 | −2.66亿 USD | −1.94亿 USD | −8073.6万 USD | −7103.8万 USD | −655.3万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6962.14万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM4229.8万0.05%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF2138.52万0.02%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO1241.85万0.07%180亿 USD0.06%US$112.27-0.35%
iShares Russell 2000 Growth ETFIWO1240.76万0.09%139.17亿 USD0.24%US$353.71-0.86%
Invesco Pharmaceuticals ETFPJP1222.64万2.23%5.48亿 USD0.58%US$123.44+0.46%
Dimensional - US Small Cap ETFDFAS937.21万0.03%338.04亿 USD0.31%US$78.17-0.23%
Schwab U.S. Small-Cap ETFSCHA734.73万0.03%217.13亿 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOInvesco Pharmaceuticals ETFPJPDimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
